Ovid Therapeutics IncNASDAQ:OVID
- LAST PRICE2.9900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 2.9900
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OVID |
|---|---|---|
| 09:32 ET | 883 | 3.13 |
| 09:36 ET | 500 | 3.07 |
| 09:38 ET | 873 | 3.12 |
| 09:56 ET | 100 | 3.12 |
| 10:08 ET | 203 | 3.09 |
| 10:14 ET | 100 | 3.1 |
| 10:15 ET | 100 | 3.1 |
| 10:24 ET | 200 | 3.11 |
| 10:30 ET | 100 | 3.11 |
| 10:33 ET | 200 | 3.105 |
| 10:39 ET | 100 | 3.1 |
| 10:44 ET | 100 | 3.1 |
| 10:46 ET | 800 | 3.1 |
| 10:48 ET | 950 | 3.11 |
| 11:00 ET | 1081 | 3.14 |
| 11:04 ET | 200 | 3.14 |
| 11:08 ET | 100 | 3.14 |
| 11:11 ET | 400 | 3.125 |
| 11:15 ET | 13845 | 3.13 |
| 11:33 ET | 200 | 3.1 |
| 11:36 ET | 1529 | 3.1 |
| 11:38 ET | 200 | 3.1 |
| 11:45 ET | 300 | 3.1 |
| 11:49 ET | 100 | 3.1 |
| 11:58 ET | 802 | 3.1 |
| 12:20 ET | 100 | 3.1 |
| 12:23 ET | 522 | 3.09 |
| 12:25 ET | 279 | 3.1 |
| 12:27 ET | 200 | 3.1 |
| 12:32 ET | 106 | 3.1 |
| 12:41 ET | 700 | 3.08 |
| 12:45 ET | 100 | 3.08 |
| 12:54 ET | 300 | 3.085 |
| 12:56 ET | 100 | 3.08 |
| 12:57 ET | 100 | 3.08 |
| 01:08 ET | 1000 | 3.1 |
| 01:10 ET | 100 | 3.1 |
| 01:21 ET | 435 | 3.085 |
| 01:35 ET | 4981 | 3.06 |
| 01:37 ET | 310 | 3.075 |
| 02:13 ET | 200 | 3.06 |
| 02:18 ET | 300 | 3.06 |
| 02:29 ET | 100 | 3.06 |
| 02:33 ET | 203 | 3.06 |
| 02:38 ET | 124 | 3.06 |
| 02:42 ET | 5166 | 3.06 |
| 02:44 ET | 1914 | 3.055 |
| 02:54 ET | 100 | 3.05 |
| 02:56 ET | 100 | 3.04 |
| 02:58 ET | 300 | 3.03 |
| 03:00 ET | 5399 | 3.02 |
| 03:12 ET | 600 | 3.02 |
| 03:14 ET | 200 | 3.01 |
| 03:18 ET | 300 | 3.01 |
| 03:20 ET | 700 | 3.02 |
| 03:30 ET | 1300 | 3.02 |
| 03:32 ET | 200 | 3 |
| 03:36 ET | 100 | 3 |
| 03:38 ET | 200 | 3 |
| 03:39 ET | 3108 | 3 |
| 03:41 ET | 265 | 3.0083 |
| 03:45 ET | 1180 | 3 |
| 03:48 ET | 200 | 3.01 |
| 03:52 ET | 374 | 3 |
| 03:54 ET | 400 | 3.01 |
| 03:56 ET | 962 | 3.01 |
| 03:57 ET | 100 | 3.01 |
| 03:59 ET | 481 | 2.99 |
Apr 5, 2024
DJ Ovid Therapeutics Initiated at Outperform by Wedbush, from 5:03AM ET on Friday Apr 05, 2024 by Dow Jones
5:03AM ET on Friday Apr 05, 2024 by Dow Jones
Apr 4, 2024
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 8:00AM ET on Thursday Apr 04, 2024 by Dow Jones
8:00AM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Ovid Therapeutics Inc | 211.4M | -4.0x | --- |
Design Therapeutics Inc | 212.4M | -3.1x | --- |
Merrimack Pharmaceuticals Inc | 214.1M | -178.4x | --- |
Galectin Therapeutics Inc | 216.7M | -4.7x | --- |
INmune Bio Inc | 203.5M | -6.5x | --- |
Compass Therapeutics Inc. | 203.6M | -4.4x | --- |
Company Information
Ovid Therapeutics Inc. is a biopharmaceutical company. The Company is focused on improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. It is engaged in advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. It develops OV888 (GV101), a potent and highly selective ROCK2 inhibitor, for the potential treatment of lesions associated with cerebral cavernous malformations and other brain disorders; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. It also has interest in the development and commercialization of soticlestat, which is a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes.
Contact Information
- Headquarters
- 441 NINTH AVENUE, 14TH FLOORNEW YORK, NY, United States 10001
- Phone
- 212-776-4381
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Jeremy Levin
- Chief Business and Financial Officer
- Jeffrey Rona
- Chief Operating Officer
- Jason Tardio
- Chief Scientific Officer
- Zhong Zhong
- Chief Compliance Officer, General Counsel, Corporate Secretary
- Thomas Perone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $211.4M |
|---|---|
Revenue (TTM) | $391.7K |
Shares Outstanding | 70.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-0.74 |
Book Value | $1.24 |
P/E Ratio | -4.0x |
Price/Sales (TTM) | 539.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15,134.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
